share_log

Treace Announces First Cases Utilizing RedPoint Intelliguide Patient Specific Instrumentation With the Adductoplasty System for Correction of Midfoot Deformities

Treace Announces First Cases Utilizing RedPoint Intelliguide Patient Specific Instrumentation With the Adductoplasty System for Correction of Midfoot Deformities

Treace宣佈首次使用RedPoint Intelliguide患者特定工具和Adductoplasty系統來修正中足畸形的案例
GlobeNewswire ·  12/05 05:15

PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty and Adductoplasty Procedures, today announced the successful completion of the first cases combining IntelliGuide PSI technology with the Adductoplasty System for a CT-based, patient specific correction personalized to the patient's unique midfoot deformity.

佛羅里達州龐特韋德拉,2024年12月4日(環球新聞社) - Treace Medical Concepts公司(「Treace」或「公司」)(NasdaqGS:TMCI)是一家醫療技術公司,通過旗艦Lapiplasty和Adductoplasty手術治療凸趾和相關中足畸形,推動外科治療發生根本性轉變,並今日宣佈成功完成首例將IntelliGuide PSI技術與Adductoplasty系統相結合進行以患者特定個性化校正的Ct掃描手術治療凸趾和相關中足畸形項目。

IntelliGuide PSI, incorporating RedPoint technology, is the first and only patient-specific cut guide system available for correction of bunion and/or midfoot deformities in the U.S. IntelliGuide PSI provides an AI-enabled software approach to convert a patient's CT-scan to a pre-operative surgical plan and produce a 3D-printed cut guide specific to the patient's deformity for efficient and personalized intra-operative guidance. It is estimated that midfoot deformities, such as metatarsus adductus, may occur in up to 30% of bunion patients.1,2

IntelliGuide PSI,融合RedPoint技術,是美國可用於校正凸趾和/或中足畸形的第一個唯一患者特定切割指導系統。IntelliGuide PSI提供了一種通過人工智能軟件方法將患者的Ct掃描轉換爲術前手術計劃,併爲特定患者的畸形制作3D打印切割指導,以實現高效個性化的術中指導。據估計,中足畸形(如橫趾畸形)可能存在於高達30%的凸趾患者身上。

Treace has now initiated a limited market release of IntelliGuide PSI for the Adductoplasty Procedure and plans to expand surgeon access of IntelliGuide for both the Lapiplasty and Adductoplasty procedures progressively over the coming months with full market release expected within the first half of 2025.

Treace現已啓動IntelliGuide PSI用於Adductoplasty手術的有限市場發佈,並計劃逐步擴大IntelliGuide對Lapiplasty和Adductoplasty手術的外科醫生訪問,並預計在2025年上半年完全發佈市場。

"IntelliGuide PSI further advances our market leadership position in the surgical management of bunion and midfoot deformities, extending the established benefits of PSI personalized approaches to our Lapiplasty and Adductoplasty Procedures," said John T. Treace, CEO, Founder and Board Member of Treace. "We look forward to further building out our ecosystem of enabling digital technologies as part of our strategy to provide a comprehensive portfolio of bunion and related midfoot solutions to address the evolving needs of our surgeon customers and patients."

「IntelliGuide PSI進一步提升了我們在凸趾和中足畸形外科管理領域的市場領先地位,將PSI個性化方法的已確立優勢擴展到我們的Lapiplasty和Adductoplasty手術,」Treace首席執行官、創始人兼董事會成員約翰·特雷斯表示。「我們期待進一步構建我們的數字技術生態系統,作爲提供全面解決方案的策略的一部分,以滿足外科醫生客戶和患者不斷髮展的需求。」

Eric Kuhlman, DPM of Center for Spine & Orthopedics in Denver, who performed an initial IntelliGuide Adductoplasty case commented, "This technology is going to revolutionize the way that I approach treating patients with bunion and related midfoot deformities. The virtual planning process helped me fully visualize the complex three-dimensional metatarsus adductus midfoot correction before stepping foot in the OR and the 3D-printed cut guides added a new level of intra-operative precision, efficiency, and confidence to the procedure. Just as PSI has advanced other areas of orthopedics, I expect IntelliGuide PSI to rapidly expand our understanding and treatment of these common, yet challenging foot deformities."

丹佛市脊柱與骨科中心(DPM),Eric Kuhlman進行了一例初步的IntelliGuide趾外翻成形術病例,並評論道:「這項技術將徹底改變我的治療趾外翻和相關蹠趾中足畸形患者的方式。虛擬規劃過程幫助我在踏入手術室之前充分可視化了複雜的三維蹠底外翻中足矯正,而3D打印的切割導板爲術中精準度、效率和信心增添了新的層次。正如PSI技術已經在其他骨科領域取得進展一樣,我期待IntelliGuide PSI將快速拓展我們對這些常見但具有挑戰性的足部畸形的理解和治療。」

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company's expectations of innovation, product commercialization, market performance, and growth. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace's public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

前瞻性聲明
本新聞稿包含根據1933年修正的證券法第27條和1934年修正的證券交易法第21條的前瞻性聲明。除了歷史事實陳述之外,所有其他聲明均爲前瞻性聲明,包括但不限於公司對創新、產品商業化、市場表現和增長的期望。前瞻性聲明基於管理層對未來事件和趨勢的當前假設和期望,這些事件和趨勢影響或可能影響公司的業務、戰略、運營或財務表現,實際結果和其他事件可能因此與此類聲明中明示或暗示的行爲大相徑庭,由於衆多風險和不確定性。前瞻性聲明本質上受到風險和不確定性的影響,其中一些是無法預測或量化的。可能導致實際結果或其他事件與本新聞稿所考慮的不同基本因素可以在Treace向證券交易委員會(SEC)的公開文件中的風險因素部分找到,包括Treace於2024年2月27日向SEC提交的截至2023年12月31日的年度10-K表格以及其後續的SEC文件。由於前瞻性聲明本質上受到風險和不確定性的影響,您不應將這些前瞻性聲明作爲未來事件的預測。這些前瞻性聲明僅代表其發表日期,除非法律要求,公司無義務更新這些聲明,無論是因任何新信息、未來發展還是其他原因。

Internet Posting of Information
Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

信息的網絡發佈
Treace定期在其網站的"投資者關係"部分發布可能對投資者重要的信息。 公司鼓勵投資者和潛在投資者定期查看Treace網站以獲取有關Treace的重要信息。

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty 3D Bunion Correction System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty and Adductoplasty procedures, as well as other common bone fusion procedures of the foot. For more information, please visit .

關於Treace Medical Concepts:Treace Medical Concepts, Inc.是一家醫療技術公司,旨在推進外科管理拇趾外翻及相關足弓畸形的護理標準。拇趾外翻是一種複雜的三維畸形,源於足部中部的不穩定關節,影響約6700萬美國人,其中Treace估計有110萬人需要每年手術治療。 Treace開創並取得了Lapiplasty 3D Bunion Correction System的專利--這是一種由儀器、植入物和外科方法組成的組合,旨在通過外科手術矯正拇趾畸形的三個平面,並固定不穩定的關節,解決拇趾畸形的根本原因,幫助病人恢復活力的生活方式。爲了進一步支持拇趾畸形患者的需求,Treace推出了Adductoplasty Midfoot Correction System,旨在重複性外科手術矯正足弓畸形,以及其Hammertoe PEEk Fixation System,旨在解決錘趾、雞爪趾和槌狀趾畸形。該公司通過推出SpeedPlate Rapid Compression Implants擴大了其足踝市場份額--這是一種具有廣泛適用性的創新固定平台,可應用於Lapiplasty和Adductoplasty手術,以及足部其他常見骨融合手術。有關更多信息,請訪問網站。
Treace Medical Concepts, Inc.是一家醫療科技公司,旨在提高泡狀骨療法和相關中足畸形外科管理標準。Bunion是複雜的三維畸形,起源於足部中間的不穩定關節,並影響約6700萬美國人,其中Treace估計有110萬人符合手術條件。Treace率先並擁有Lapiplasty 3D Bunion矯正系統的專利——該系統是一套儀器、植入物和手術方法的組合,旨在手術矯正泡狀骨畸形的三個平面並固定不穩定的關節,解決泡狀骨的根本原因,幫助患者恢復活躍生活方式。爲進一步支持泡狀骨患者的需求,Treace推出了Adductoplasty Midfoot矯正系統,旨在可重複手術矯正中足畸形。該公司繼續擴展在足踝市場的影響力,推出了其SpeedPlate Rapid壓縮植入物,這是一種創新的固定平台,廣泛適用於Lapiplasty和Adductoplasty手術,以及足部其他常見骨融合手術。欲了解更多信息,請訪問 .

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

要了解更多關於Treace的信息,請與我們聯繫。 LinkedIn, X, FacebookInstagram.

1. Aiyer AA, et al. Foot Ankle Int. 2014; 35:1292-1297.
2. Gribbin CK, et al. Foot Ankle Int. 2017; 38:14-19.

1. Aiyer AA等人。《足踝國際雜誌》。2014; 35:1292-1297。
2. Gribbin Ck等人。《足踝國際雜誌》。2017; 38:14-19。

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

聯繫人:
Treace Medical Concepts
馬克·L·黑爾
首席財務官
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net

投資者:
吉爾馬丁集團
Vivian Cervantes
IR@treace.net


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論